As a single agent, AMG386 reduced tumor vascular p‐TIE2 (Fig 6C and D) and p‐EphrinB (Fig 6E and F); these results are consistent with Ang2 activation of p‐TIE2 and p‐EphrinB in primary endothelial cells (Fig 1H). Here, TEK is linked to neoplasm.